A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19

Michael E. Bowdish(Cedars-Sinai Medical Center), Annetine C. Gelijns(Icahn School of Medicine at Mount Sinai), Nimesh D. Desai(University of Pennsylvania), Alan J. Moskowitz(Icahn School of Medicine at Mount Sinai), Abhijit Duggal, Michael J. Mack(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Mary E. Marks(Boston University), Andrew M. Vekstein, Helena Chang(Icahn School of Medicine at Mount Sinai), Tammie Possemato(University of Southern California), Alexander Iribarne(Dartmouth–Hitchcock Medical Center), Jessica Overbey(Berry & Associates (United States)), Jonathan Hupf(Institute of Population and Public Health), Sam Parnia(New York University), Francis D. Pagani(Michigan Medicine), Athos J. Rassias(Dartmouth–Hitchcock Medical Center), Beth Hollister(Duke University), Jonathan L. Golob(University of Michigan), Jack Hayes(Mesoblast (United States)), A. Marc Gillinov(Cleveland Clinic), Keren Osman(Tisch Hospital), Patrick T. O’Gara(Brigham and Women's Hospital), Silviu Itescu(Mesoblast (United States)), Bradley G. Leshnower(Emory University), Ellen Moquete(Icahn School of Medicine at Mount Sinai), Emilia Bagiella(Icahn School of Medicine at Mount Sinai), Eustace Fernandes(Lutheran Medical Group), Peter C. Hou(Brigham and Women's Hospital), Nirav Patel(Northwell Health), Judson B. Williams(WakeMed), Elizabeth Burke(Mesoblast (United States)), Peter K. Smith(Duke University), Christian Romero(University of Southern California), Karen O’Sullivan(Icahn School of Medicine at Mount Sinai), Robert Gottlieb(Baylor University Medical Center), Fred Grossman, Christina E. Barkauskas(Duke University)
American Journal of Respiratory and Critical Care Medicine
September 13, 2022
Cited by 71


Related Papers